Figure 1From: Risk of hyperkalemia in patients with moderate chronic kidney disease initiating angiotensin converting enzyme inhibitors or angiotensin receptor blockers: a randomized study Flow diagram of participants through each stage of the trial indicating for each group the number of participants assigned that received intended treatment and were analyzed for the primary outcome. Back to article page